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Background: Ligustrazine has potent effects of thrombolysis, neuroprotection and vascular protection, which
were important for effectively protecting the nervous system. Previous study in our laboratory reported that
ligustrazine-benzoic acid derivatives have been shown to exhibit beneficial effect against CoCl2-induced neurotoxicity
in differentiated PC12 cells. To further improve ligustrazine’s neuroprotection, we integrated the ligustrazine and
phenolic acid fragments into one molecule via an amide bond based on structural combination.
Results: In this study, 12 novel ligustrazine-phenolic acid derivatives were synthesized and nine others were
prepared by improved methods. Furthermore, these compounds were evaluated for their protective effects
against CoCl2-induced neurotoxicity in differentiated PC12 cells. The amides conjunctional derivatives exhibited
promising neuroprotective activities in comparison with ligustrazine. In addition, the most active congener
(E)-3-(2,3,4-trimethoxyphenyl)-N-((3,5,6-trimethylpyrazin-2-yl)methyl)acrylamide (L10, EC50 = 25 μM), which is 2
times higher than that of ligustrazine, may be a potential candidate for intervention in neurological diseases.
Structure-activity relationship was discussed briefly.
Conclusions: Results of series of ligustrazinyl amides enrich the study of ligustrazine derivatives with
neuroprotective effects. Our completed work supports that the attempt to apply structure combination to
discover more efficient neuroprotection lead compounds is viable.
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Neurological disorders, such as Stroke, Alzheimer’s dis-
ease (AD) and Parkinson’s disease (PD), threaten mil-
lions of patients with ever growing numbers in ageing
societies [1-3]. To discover drugs with nerve functional
recovery as a treatment or prevention of neurological
disorder is of great significance [4]. To date, despite the
remarkable progress achieved in theory, effective ap-
proaches to recover damaged nerve are not yet to be
found [1,5]. Therefore, to discover more effective drugs
for the treatment in injured nerve cell remains an im-
portant area of drug discovery [6,7].* Correspondence: wpl581@126.com; hm_lei@126.com
1School of Chinese Pharmacy, Beijing University of Chinese Medicine, No.6
Wangjing Middle Ring South Road, Beijing, Chaoyang District, China
Full list of author information is available at the end of the article
© 2015 Li et al.; licensee Springer. This is an O
Attribution License (http://creativecommons.
reproduction in any medium, provided the o
Dedication waiver (http://creativecommons.o
unless otherwise stated.Nowadays, many new drugs have been generated
from natural products [8-11]. Ligustrazine (2,3,5,6-
tetramethylpyrazine, TMP), derived from the traditional
Chinese medicine Rhizoma Chuanxiong (Ligusticum
chuanxiong Hort.) which was widely used to treat
Stroke and cerebrovascular disease (CVD) in China
[12,13]. Recent studies have indicated that ligustrazine
has potent effects of thrombolysis, neuroprotection and
vascular protection, which were important for effect-
ively protecting the nervous system [14-21]. In
addition, many phenolic acid ingredients, such as caf-
feic acid, protocatechuic acid, salicylic acid, ferulic acid,
vanillic acid, etc., also showed interesting neuroprotec-
tive activities [21-24].
To further improve ligustrazine’s neuroprotective
effect, inspired by the potent neuroprotective effects ofpen Access article distributed under the terms of the Creative Commons
org/licenses/by/4.0) which permits unrestricted use, distribution, and
riginal work is properly credited. The Creative Commons Public Domain
rg/publicdomain/zero/1.0/) applies to the data made available in this article,
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ligustrazine and phenolic acid fragments into one mol-
ecule based on structural combination [17,21,25]; a
series of novel ligustrazine-benzoic analogues was con-
structed via an amide bond rather than an ester bond in
our previous research on ligustrazine-benzoic acid deriv-
atives. A recent study has reported that part of ligustra-
zinyl amides congener structures exhibited good
proliferative activities on human umbilical vascular
endothelial cells (HUVECs) [25]. Their protective
effects against neurotoxicity were evaluated in differen-
tiated PC12 cells. Structure-activity relationship was
discussed briefly.Results and discussion
Chemistry
All the target compounds were synthesized via the routes
outlined in Scheme 1, Scheme 2 and Scheme 3. The key
intermediate (3,5,6-trimethylpyrazin-2-yl)methanamine (L)
was prepared according to our previous study with minor
improvements. Compound B (TMP-Br) was synthesized
from anhydrous ligustrazine and N-bromosuccinimide
(NBS) in carbon tetrachloride via free radical reaction, the
crude product was used directly in the next reaction with-
out further purification. The mixture of TMP-Br and
phthalimide potassium in CH3CN that was refluxing for
2 h gave compound C. Intermediate L was obtained by re-
action of C and 80% hydrazine hydrate in absolute ethanol
refluxing for 5 h.
The single-step coupling reaction between L and the
cinnamic acids were performed using EDCI and
(CH3CH2)3 N in anhydrous CH2Cl2, to afford ligustra-
zine derivatives (L1–L10, as shown in Method 1 of
Scheme 2). In Method 2 and 3, the carboxylic acids and
HOBt were firstly transformed to active ester in the
presence of EDCI, and then reacted with compound L,
obtaining the target compounds (L11–15, L17–21).
In Scheme 3, the starting compound 16 was first per-
benzylated and then transformed to free carboxylic acid.
The coupling reaction between L and the hydroxyl-
perbenzylated benzoic acid 16b was performed using
EDCI and HOBt in anhydrous CH2Cl2. A final deprotec-
tion step afforded the targeted compound L16. The
chemical structures of all target compounds (Table 1)Scheme 1 Synthetic routes to ligustrazine intermediate L. Reagents an
potassium, reflux, 2 h, 64%; (iii) CH3CH2OH, N2H4 · H2O, reflux, 5 h, 88%.were confirmed by 1H-NMR, 13C-NMR and high reso-
lution mass (HRMS).
Biological activities
Protective effect on injured neuronal-like PC12 cells
Setting ligustrazine as the positive control drug, all the
synthesized compounds were tested for their protective
effects on neuronal-like PC12 cells damaged by CoCl2.
The proliferation rates (P%) of injured PC12 cells were
assessed by methyl thiazolyl tetrazolium (MTT) assay.
The proliferation rates (%) at different concentration
and 50% effective concentrations (EC50) for protecting
damaged PC12 cells of the ligustrazine derivatives were
outlined in Table 2.
From the obtained results, it was observed that ligus-
trazine and most of its derivatives presented protective
effects on injured differentiated PC12 cells, and several
ligustrazine derivatives exhibited competitive positive ac-
tivities (with lower EC50 values) than TMP (EC50 =
65 μM). Among them, L10 and L11 displayed promising
neuroprotective activities (EC50 = 25, 27 μM, respect-
ively), in which compound L10 presented 2 times higher
potency than TMP.
Among L1–L10, compounds that introduced methyl
and methoxy group on the phenyl ring performed better
neuroprotective activities than L1 without any group
substituted. It can be concluded that with the increase of
the number of methoxy group at the phenyl moiety, the
activities increase considerably (L10 > L3, L6, L8 > L4,
L5, L7). However, this rule did not work in the case of
L9 (EC50 = 102 μM) on the injured PC12 cells model.
The structure-activity relationship analysis was consist-
ent with the protective effects of ligustrazine-based stil-
bene derivatives on damaged ECV-304 cells [26]. These
findings may provide a new framework for the design of
new ligustrazine derivatives as neuroprotective drugs.
It should be noticed that ligustrazinyl amides L12–
L16 with phenolic hydroxyl substituted approximately
followed a tendency in activity 4-OH, 3-OCH3 > 4-OH >
2-OH > 3-OH > 3, 4-OH. This was similar to our previ-
ous research that the ligustrazine-benzoic acid deriva-
tives were synthesized via an ester bond [21]. Moreover,
compounds L15 and L11 were derived from salicylic
acid and acetylsalicylic acid, respectively. But L11 (EC50 =
27 μM) displayed observable protective action, and it isd Conditions: (i) CCl4, NBS, hv, reflux, 2 h, 65%; (ii) CH3CN, phthalimide
Scheme 2 Synthetic routes to ligustrazine derivatives L1–L15, L17–L21. Reagents and Conditions: (i) anhydrous CH2Cl2, EDCI/(CH3CH2)3 N, r.
t., 12 h; (ii) anhydrous DMF (L11 anhydrous CH2Cl2), EDCI/HOBt, r.t., 12 h; (iii) anhydrous DMF (L21 DMI), EDCI/HOBt, r.t., 12 h.
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acetyl group may be an effective group, led to improve-
ment of the neuroprotective activities. In addition, the
introduction of trans olefinic bond may contribute to en-
hance the neuroprotective activity, such as L20 > L12,
L17 > L13, L19 > L15 and L21 > L16.
Furthermore, previous studies proved that compounds
L2, L4, L19 and L20 could stimulate the proliferation of
cultured human umbilical vascular endothelial cells [25];
current study also exhibited that L2, L4, L19 and L20
exhibited neuroprotective activities. Based on the above
evidences, we reason that the new synthetic ligustraziny-
lated derivatives possess multiple pharmacological activ-
ities such as neuroprotection and protection against
vascular endothelial cell injury, suggesting that they may
be more efficacious than either a neuroprotective agent
or vascular protective drug alone.
Effects of L10 on PC12 cells in morphology
Observed under optical microscopy (OLMPUS, Japan),
as shown in Figure 1-A, we found that undifferentiatedScheme 3 Synthetic routes to ligustrazine derivatives L16. Reagents a
CH3CH2OH, 10% KOH, 70°C, 2 h; (iii) TMP-NH2, DMF, EDCI/HOBt, r.t., 12 h; (ivPC12 cells that maintained under normal conditions
were small and proliferated to form clone-like cell clus-
ters without neural characteristics. By exposure to NGF,
normal differentiated PC12 cells showed fine dendritic
networks similar to those nerve cells (Figure 1-B). In
contrast, CoCl2-insulted differentiated PC12 cells devel-
oped mild cell body swelling and some cells shrunk the
dendritic networks even lost neurites demonstrating
round shape (Figure 1-C). Pretreatment with L10 allevi-
ated morphological manifestations of cells damage com-
pared to model cells (Figure 1-D).
Conclusions
In this work, 21 novel ligustrazine-phenolic acid deriva-
tives were designed, synthesized and biologically evalu-
ated for their protective effects against CoCl2-induced
neurotoxicity in differentiated PC12 cells. The biological
results have demonstrated that most of ligustrazine
derivatives exhibited better neuroprotective activities in
comparison with ligustrazine. In addition, the most
active congener L10 (EC50 = 25 μM), which is 2 timesnd Conditions: (i) DMF, benzyl bromide, K2CO3, 85°C, 12 h; (ii) H2O/
) CH3OH, Pd/C, H2, r.t., 12 h.
Table 1 The structures of ligustrazine derivatives L1–21
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Table 2 EC50 of the ligustrazine derivatives for protecting
damaged PC12 cells
Compound Proliferation rate (%) EC50
(μM)60 μM 30 μM 15 μM 7.5 μM 3.75 μM
L1 −20.01 −14.71 5.47 −8.63 −15.83 150
L2 18.94 18.52 12.48 2.80 −10.53 74
L3 38.69 14.19 12.04 −0.57 −7.52 64
L4 8.91 9.20 11.86 4.92 1.61 77
L5 3.28 4.31 13.63 9.98 1.79 78
L6 8.68 30.75 9.73 9.06 3.07 62
L7 7.63 9.29 17.83 11.37 0.51 71
L8 3.00 7.39 54.75 35.16 0.06 46
L9 6.05 7.50 −3.24 −3.46 −8.38 102
L10 47.63 38.14 36.80 35.01 21.74 25
L11 46.64 43.34 33.42 24.46 22.52 27
L12 26.42 19.94 13.47 13.29 10.75 53
L13 3.35 4.89 40.02 14.72 −6.53 64
L14 −13.55 9.81 16.80 1.94 −11.97 98.
L15 −1.40 17.23 25.56 10.54 −19.67 92
L16 −8.69 −2.40 13.41 −1.28 −1.36 103
L17 11.58 28.77 39.01 10.12 −20.20 60
L18 0.05 0.31 8.58 −0.51 −8.65 101
L19 17.95 19.80 22.80 24.53 24.06 44
L20 13.94 19.41 25.05 28.12 34.42 40
L21 27.59 28.12 29.80 25.51 24.52 36
TMP 14.71 12.11 11.76 10.60 9.44 65
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candidate for intervention in neurological diseases. Further-
more, structure-activity relationship was discussed briefly.
Altogether, results of series of ligustrazinyl amides
enrich the study of ligustrazine derivatives with neuro-
protective effects. Our completed work supports that the
attempt to apply structure combination to discover more
efficient neuroprotection lead compounds is viable. Fur-
thermore, to pursue the optimized neuroprotective
agents, ligustrazine-cinnamic acid ether and ligustrazine-
cinnamic acid ester derivatives’ neuroprotective effects
are ongoing in our lab.Experimental section
Chemistry
Materials and methods
Reactions were monitored by TLC which was performed
on silica gel GF254 (Qingdao Haiyang Chemical Co.,
China) and spots were visualized by modified bismuth
potassium iodide or by irradiation with UV light
(254 nm). Nuclear magnetic resonance spectra were
recorded using a Bruker AVANCE 500 NMR spectrom-
eter (Fällanden, Switzerland) in the indicated solvents.
Chemical shifts are expressed in δ (ppm) relative to tet-
ramethylsilane (TMS). Coupling constants are reported
in Hertz (Hz). HRMS spectra were recorded on a
Thermo Scientific™ LTQ Orbitrap XL hybrid FTMS
instrument (Thermo Technologies, USA). Melting
points (uncorrected) were metered on an X-5 micro
melting point apparatus (Beijing, China). Flash column
Figure 1 Effects of L10 on differentiated PC12 cell injury in morphology (×200). (A) Control PC12 cells maintained under normal conditions.
(B) PC12 cells exposed to NGF. (C) Differentiated PC12 cells exposed to CoCl2 insult. (D) Differentiated PC12 cells pre-incubated with L11 then exposed
to CoCl2 insult.
Li et al. Chemistry Central Journal  (2015) 9:9 Page 6 of 9chromatography was performed on 200–300 mesh silica
gel. All chemicals used were analytical. Solvents were re-
agent grade or high-performance liquid chromatography
grade, and when necessary, were dried by standard
methods. Concentration of the reaction solutions in-
volved the use of rotary evaporator at reduced pressure.
The yields were calculated by the last step reaction.
Among all target compounds, L1, L2, L4, L8, L11, L13,
L15, L17, L20 were reported in Liu’s research [25].
Therefore, HRMS were supplemented to confirm the
chemical structures.
Preparation of (3,5,6-trimethylpyrazin-2-yl)methanamine (L)
The target compound L was synthesized by three steps.
Compound B was prepared according to our previously
reported method [27]. The crude product, which caused
a strong mucous membrane irritation, could be used in
the next step without further purification. To a solution
of B (5.750 g, 27.00 mmol) in acetonitrile (100 mL),
phthalimide potassium (5.000 g, 27.00 mmol) was added.
The mixture was refluxing for 2 h, then concentrated
under reduced pressure to afford compound C
(4.878 g, 64%), white solid. m.p.:155.3-156.8, HRMS
(ESI) m/z: 282.12381 [M + H]+, calcd. for C16H15N3O2
282.12425. The compound C was purified by flash
column chromatography and recrystallization from acet-
one [28]. The important intermediate L was obtained bythe reaction of C (4.000 g, 14.23 mmol) and 80% hydra-
zine hydrate (N2H4 · H2O, 0.85 mL) in absolute ethyl alco-
hol (100 mL) refluxing for 5 h. The solution was filtered,
concentrated under reduced pressure. The residue was
dissolved in dichloromethane, filtered and recovered
methylene chloride to give a pale yellow semi-solid
substance L (3.521 g, 88%), HRMS (ESI) m/z: 152.11829
[M+H]+, calcd. for C8H13N3 152.12827.
Preparation of L1–L10
To a solution of L (1.324 mmol) and the corresponding
cinnamic acids (1.322 mmol) in anhydrous CH2Cl2
(20 mL), EDCI (253 mg, 1.324 mmol) and triethylamine
((CH3CH2)3 N, 3.97 mmol) were added. The mixture
was stirred at room temperature for 12 h. Then washed
with water (2 × 20 mL) and brine (20 mL), successively,
dried over sodium sulfate, filtered, and concentrated
under vacuum. The residue was purified by flash chro-
matography and recrystallization from acetone.
N-((3,5,6-trimethylpyrazin-2-yl)methyl)cinnamamide
(L1): White solid, yield: 90.7%. HRMS (ESI) m/z:
282.15988 [M +H]+, calcd. for C17H19N3O 282.16064.
(E)-3-(p-tolyl)-N-((3,5,6-trimethylpyrazin-2-yl)methyl)
acrylamide (L2): White solid, yield: 83.5%. HRMS (ESI) m/
z: 296.17554 [M+H]+, calcd. for C18H21N3O 296.17629.
(E)-3-(3,4-dimethoxyphenyl)-N-((3,5,6-trimethylpyrazin-2-
yl)methyl)acrylamide (L3): White solid, yield: 86.3%, m.p.:
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15.6 Hz, 1H), 7.24 (s, 1H), 7.12 (d, J = 8.3 Hz, 1H), 7.07 (s,
1H), 6.86 (d, J = 8.3 Hz, 1H), 6.45 (d, J = 15.6 Hz, 1H), 4.61
(d, J = 3.7 Hz, 2H), 3.92 (s, 3H), 3.91 (s, 3H), 2.53 (s, 3H),
2.50 (br, 6H); 13C NMR (125 MHz, CDCl3): δ 166.2, 150.7,
149.8, 149.2, 147.9, 145.1, 141.0, 128.0, 122.1, 118.6, 111.2,
109.9, 56.1, 56.0, 41.4, 21.5, 21.5, 20.2. HRMS (ESI) m/z:
342.18167 [M+H]+, calcd. for C19H23N3O3 342.18177.
(E)-3-(4-methoxyphenyl)-N-((3,5,6-trimethylpyrazin-2-yl)
methyl)acrylamide (L4): White solid, yield: 85.8%. HRMS
(ESI) m/z: 312.17093 [M+H]+, calcd. for C18H21N3O2
312.17120.
(E)-3-(2-methoxyphenyl)-N-((3,5,6-trimethylpyrazin-2-yl)
methyl)acrylamide (L5): White solid, yield: 90.1%, m.p.:
153.3–153.8°C. 1H NMR (500 MHz, CDCl3): δ 7.95 (d, J =
15.8 Hz, 1H), 7.52 (d, J = 7.5 Hz, 1H), 7.33 – 7.30 (m,1H),
7.25 (s, 1H), 6.96 – 6.93 (m, 1H), 6.91 (d, J = 8.3 Hz, 1H),
6.67 (d, J = 15.8 Hz, 1H), 4.61 (d, J = 3.9 Hz, 2H), 3.88 (s,
3H), 2.52 (s, 3H),2.51 (s, 3H), 2.50 (s, 3H); 13C NMR
(125 MHz, CDCl3): δ 166.6, 158.3, 149.7, 148.0, 145.2,
136.5, 130.9, 128.9, 124.0, 121.5, 120.7, 111.2, 55.5, 41.4,
21.5, 20.2. HRMS (ESI) m/z: 312.17102 [M+H]+, calcd.
for C18H21N3O2 312.17120.
(E)-3-(2,3-dimethoxyphenyl)-N-((3,5,6-trimethylpyrazin-
2-yl)methyl)acrylamide (L6): White solid, yield: 83.6%,
m.p.: 182.7–183.4°C. 1H NMR (500 MHz, CDCl3): δ 7.94
(d, J = 15.9 Hz, 1H), 7.31 (s, 1H), 7.16 (d, J = 7.8 Hz, 1H),
7.06 – 7.03 (m, 1H), 6.91 (d, J = 8.0 Hz, 1H), 6.64 (d, J =
15.9 Hz, 1H), 4.61 (d, J = 2.7 Hz, 2H), 3.87 (s, 3H), 3.85 (s,
3H), 2.51 (s, 3H), 2.50 (br, 6H); 13C NMR (125 MHz,
CDCl3): δ 166.3, 153.3, 149.9, 148.4, 148.1, 148.0, 145.1,
135.8, 129.3, 124.3, 122.5, 119.5, 113.5, 61.4, 56.0, 41.5,
21.6, 21.6, 20.3. HRMS (ESI) m/z: 342.18155 [M+H]+,
calcd. for C19H23N3O3 342.18177.
(E)-3-(3-methoxyphenyl)-N-((3,5,6-trimethylpyrazin-2-yl)
methyl)acrylamide (L7): White solid, yield: 91.3%, m.p.:
117.2–117.9°C. 1H NMR (500 MHz, CDCl3): δ 7.64 (d, J =
15.6 Hz, 1H), 7.32 (s, 1H), 7.30 – 7.27 (m, 1H), 7.14
(d, J = 7.3 Hz, 1H), 7.06 (s, 1H), 6.90 (d, J = 7.9 Hz,
1H), 6.56 (d, J = 15.6 Hz, 1H), 4.60 (s, 2H), 3.83 (s,
3H), 2.53 (s, 3H), 2.50 (br, 6H); 13C NMR (125 MHz,
CDCl3): δ 165.9, 159.9, 149.8, 148.0, 147.9, 144.9,
141.1, 136.3, 129.9, 121.0, 120.6, 115.5, 113.1, 55.4,
41.4, 21.5, 21.5, 20.2. HRMS (ESI) m/z: 312.17117 [M+H]+,
calcd. for C18H21N3O2 312.17120.
(E)-3-(2,5-dimethoxyphenyl)-N-((3,5,6-trimethylpyrazin-2-
yl)methyl)acrylamide (L8): White solid, yield: 88.5%. HRMS
(ESI) m/z: 342.18118 [M+H]+, calcd. for C19H23N3O3
342.18177.
(E)-3-(3,4,5-trimethoxyphenyl)-N-((3,5,6-trimethylpyrazin-
2-yl)methyl)acrylamide (L9): White solid, yield: 81.6%, m.p.:
154.7–155.4°C. 1H NMR (500 MHz, CDCl3): δ 7.60 (d, J =
15.5 Hz, 1H), 7.29 (s, 1H), 6.77 (s, 2H), 6.48 (d, J = 15.5 Hz,
1H), 4.61 (s, 2H), 3.89 (s, 6H), 3.87 (s, 3H), 2.53 (s, 3H),2.50 (br, 6H); 13C NMR (125 MHz, CDCl3): δ 165.9, 153.5,
149.9, 148.0, 147.9, 144.9, 141.2, 139.5, 130.5, 120.0, 105.1,
61.1, 56.3, 41.4, 21.6, 21.5, 20.2. HRMS (ESI) m/z:
372.19232 [M+H]+, calcd. for C20H25N3O4 372.19233.
(E)-3-(2,3,4-trimethoxyphenyl)-N-((3,5,6-trimethylpyrazin-
2-yl)methyl)acrylamide (L10): White solid, yield: 85.2%, m.
p.: 139.8–140.5°C. 1H NMR (500 MHz, CDCl3): δ 7.81 (d,
J = 15.8 Hz, 1H), 7.26 (d, J = 8.6 Hz, 1H),7.24 (s, 1H), 6.68
(d, J = 8.6 Hz, 1H), 6.59 (d, J = 15.8 Hz, 1H), 4.61 (d, J =
1.8 Hz, 2H), 3.91 (s, 3H), 3.88 (s, 3H), 3.88 (s, 3H), 2.52 (s,
3H), 2.51 (br, 6H); 13C NMR (125 MHz, CDCl3): δ 166.6,
155.0, 153.2, 149.8, 148.0, 147.9, 145.2, 142.5, 136.1, 123.4,
122.0, 120.1, 107.6, 61.4, 61.0, 56.1, 41.4, 21.6, 21.5,
20.2. HRMS (ESI) m/z: 372.17950 [M + H]+, calcd. for
C20H25N3O4 372.19233.
Preparation of L11–L15, L17–L21
Intermediate L (1.324 mmol) and the corresponding
phenolic acids (1.322 mmol) were dissolved in anhyd-
rous DMF (L11 CH2Cl2, L21 DMI) (20 mL), EDCI
(253 mg, 1.324 mmol) and HOBt (59 mg, 0.44 mmol)
were added. The mixture was stirred at room
temperature under nitrogen atmosphere for 12 h. The
reaction mixture was washed with water (2 × 20 mL) and
brine (20 mL), dried over sodium sulfate, filtered, and
concentrated under vacuum. The residue was purified
by colume chromatography and recrystallization from
methanol to give L11–L15 and L17–L21.
2-(((3,5,6-trimethylpyrazin-2-yl)methyl)carbamoyl)
phenyl acetate (L11): White solid, yield: 68.9%. HRMS
(ESI) m/z: 336.13163 [M +Na]+, calcd. for C17H19N3O3
336.13241.
4-hydroxy-3-methoxy-N-((3,5,6-trimethylpyrazin-2-yl)
methyl)benzamide (L12): White solid, yield: 81.8%, m.p.:
171.3–172.0°C. 1H NMR (500 MHz, CDCl3): δ 7.84 (s,
1H), 7.52 (d, J = 1.5 Hz, 1H), 7.35 (dd, J = 8.2, 1.5 Hz,
1H), 6.95 (d, J = 8.2 Hz, 1H), 6.40 (s, 1H), 3.93 (s, 3H),
2.52 (br, 6H), 2.51 (s, 3H); 13C NMR (125 MHz, CDCl3):
δ 167.0, 149.9, 149.0, 148.0, 148.0, 146.8, 145.2, 126.6,
120.0, 114.2, 110.6, 56.1, 41.5, 21.6, 21.5, 20.2. HRMS
(ESI) m/z: 302.15002 [M +H]+, calcd. for C16H19N3O3
302.15047.
4-hydroxy-N-((3,5,6-trimethylpyrazin-2-yl)methyl)benza-
mide (L13): White solid, yield: 76.9%. HRMS (ESI) m/z:
272.13925 [M+H]+, calcd. for C15H17N3O2 272.13990.
3-hydroxy-N-((3,5,6-trimethylpyrazin-2-yl)methyl)ben-
zamide (L14): White solid, yield: 78.4%, m.p.: 210.4–
211.3°C. 1H NMR (500 MHz, DMSO-d6): δ 9.64 (s, 1H),
8.76 (t, J = 5.0 Hz, 1H), 7.31 – 7.19 (m, 3H), 6.90 (dd, J =
7.8, 1.3 Hz, 1H), 4.51 (d, J = 5.2 Hz, 2H), 2.46 (s, 3H),
2.41 (br, 6H); 13C NMR (125 MHz, DMSO-d6): δ 166.2,
157.3, 149.1, 147.9, 147.8, 147.4, 135.7, 129.3, 118.1,
117.8, 114.3, 42.1, 21.1, 21.1, 20.3. HRMS (ESI) m/z:
272.13913 [M +H]+, calcd. for C15H17N3O2 272.13990.
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mide (L15): White solid, yield: 84.3%. HRMS (ESI) m/z:
272.13943 [M+H]+, calcd. for C15H17N3O2 272.13990.
(E)-3-(4-hydroxyphenyl)-N-((3,5,6-trimethylpyrazin-2-yl)
methyl)acrylamide (L17): Little yellow solid, yield: 71.3%.
HRMS (ESI) m/z: 296.14035 [M-H]−, calcd. for
C17H19N3O2 296.13990.
(E)-3-(3-hydroxyphenyl)-N-((3,5,6-trimethylpyrazin-2-yl)
methyl)acrylamide (L18): Little yellow solid, yield: 74.8%,
m.p.:196.3–197.0°C. 1H NMR (500 MHz, DMSO-d6): δ
9.60 (s, 1H), 8.52 (t, J = 5.0 Hz, 1H), 7.35 (d, J = 15.8 Hz,
1H), 7.20 (t, J = 7.8 Hz, 1H), 6.97 (d, J = 7.5 Hz, 1H), 6.93
(s, 1H), 6.77 (d, J = 8.0 Hz, 1H), 6.65 (d, J = 15.8 Hz, 1H),
4.47 (d, J = 5.2 Hz, 2H), 2.46 (s, 3H), 2.43 (s, 3H), 2.42 (s,
3H); 13C NMR (125 MHz, DMSO-d6): δ 164.8, 157.7,
149.4, 148.0, 147.8, 147.1, 139.2, 136.1, 129.9, 121.7, 118.8,
116.7, 113.7, 41.7, 21.1, 21.0, 20.2. HRMS (ESI) m/z:
296.14037 [M-H]−, calcd. for C17H19N3O2 296.13990.
(E)-3-(2-hydroxyphenyl)-N-((3,5,6-trimethylpyrazin-2-yl)
methyl)acrylamide (L19): Little yellow solid, yield: 77.2%,
m.p.: > 210°C. 1H NMR (500 MHz, DMSO-d6): δ 10.03 (s,
1H), 8.47 (t, J = 5.0 Hz, 1H), 7.66 (d, J = 15.9 Hz, 1H), 7.42
(d, J = 7.5 Hz, 1H), 7.17 (t, J = 7.6 Hz, 1H), 6.88 (d, J =
8.1 Hz, 1H), 6.81 (t, J = 7.4 Hz, 1H), 6.74 (d, J = 15.9 Hz,
1H), 4.46 (d, J = 5.2 Hz, 2H), 2.46 (s, 3H), 2.43 (s, 3H), 2.42
(s, 3H); 13C NMR (125 MHz, DMSO-d6): δ 165.4, 156.3,
149.4, 148.0, 147.8, 147.3, 134.8, 130.5, 128.1, 121.6, 121.3,
119.3, 116.1, 41.7, 21.1, 21.0, 20.3. HRMS (ESI) m/z:
296.14047 [M-H]−, calcd. for C17H19N3O2 296.13990.
(E)-3-(4-hydroxy-3-methoxyphenyl)-N-((3,5,6-trimethyl-
pyrazin-2-yl)methyl)acrylamide (L20): Little yellow solid,
yield: 80.1%. HRMS (ESI) m/z: 326.15090 [M-H]−, calcd.
for C18H21N3O3 326.15047.
(E)-3-(3,4-dihydroxyphenyl)-N-((3,5,6-trimethylpyrazin-2-yl)
methyl)acrylamide (L21): Little yellow solid, yield: 64.3%, m.
p.: > 210°C. 1H NMR (500 MHz, DMSO-d6): δ 9.43 (s, 1H),
9.20 (s, 1H), 8.42 (t, J= 4.9 Hz, 1H), 7.26 (d, J= 15.7 Hz, 1H),
6.96 (s, 1H), 6.83 (d, J= 7.9 Hz, 1H), 6.75 (d, J= 8.1 Hz, 1H),
6.43 (d, J= 15.7 Hz, 1H), 4.45 (d, J= 4.9 Hz, 2H), 2.45 (s, 3H),
2.42 (s, 3H), 2.41 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ
165.3, 149.3, 147.9, 147.8, 147.3, 147.3, 145.5, 139.5, 126.3,
120.4, 118.2, 115.8, 113.9, 41.7, 21.0, 21.0, 20.2. HRMS
(ESI) m/z: 336.13140 [M+Na]+, calcd. for C17H19N3O3
336.13241.
Preparation of L16
The desired compound 16b was gained according to the
method described by Kojima and Tranchimand with
minor modifications [29,30]. EDCI (0.253 g, 1.324 mmol)
and HOBt (0.059 g, 0.44 mmol) were added to a stirred
solution of 16b (0.442 g, 1.324 mmol) and the inter-
mediate L (1.324 mmol) in anhydrous CH2Cl2 (20 mL).
The mixture was stirred at room temperature for 12 h.
The mixture was washed with water (2 × 20 mL) andbrine (20 mL), dried over sodium sulfate, filtered, and
concentrated under vacuum. Flash chromatography
afforded 16c (0.566 g, 91.6%), white solid, m.p.: 127-
128°C, HRMS (ESI) m/z: 490.21033 [M +Na]+, calcd. for
C29H29N3O3 490.21066. To a solution of 16c (0.48 g,
1.028 mmol) in methanol (20 mL), was added Pd/C 10%
(0.01 g). Then the suspension was stirred under hydro-
gen atmosphere at room temperature for 12 h. The mix-
ture was filtered, washed with methanol (2 × 20 mL),
and methanol evaporated under vacuum to afford L16.
3,4-dihydroxy-N-((3,5,6-trimethylpyrazin-2-yl)methyl)
benzamide (L16): White solid, yield: 93.7%, m.p.: > 210°C.
1H NMR (500 MHz, DMSO-d6): δ 9.45 (s, 1H), 9.13
(s, 1H), 8.52 (t, J = 5.0 Hz, 1H), 7.29 (s, 1H), 7.22 (d, J =
8.2 Hz, 1H), 6.74 (d, J = 8.2 Hz, 1H), 4.48 (d, J = 5.0 Hz,
2H), 2.45 (s, 3H), 2.41 (s, 6H); 13C NMR (125 MHz,
DMSO-d6): δ 165.9, 149.0, 148.4, 147.8, 147.5, 144.8,
125.5, 119.0, 115.1, 114.8, 42.1, 21.0, 21.0, 20.2. HRMS
(ESI) m/z: 288.12699 [M+H]+, calcd. for C15H17N3O3
288.13482.Bio-evaluation methods
Protective effect on damaged differentiated PC12 cells
The PC12 cell line (pheochromocytoma) was purchased
from Institute of Materia Medica of Chinese Academy of
Medical Science. Cells were growed in RPMI 1640
medium supplemented with 5% (v/v) fetal bovine serum
(FBS), 10% (v/v) heat inactivated horse serum and 100
U/mL penicillin-streptomycin (Thermo Technologies,
USA) and incubated at 37°C in a humidified atmosphere
of 5% CO2. When cells achieved the desired density of >
80% confluency original medium was removed and cells
were maintained with serum-free media for 14 h. The
cells were resuspended in new growth media which con-
sisted of RPMI 1640 supplemented with 10% heat inacti-
vated fetal bovine serum. Cells were plated on 96-well
dishes pre-coated with poly-L-lysine at 7 × 103 cells/well,
differentiated by treated with 50 ng/mL NGF for 48 h.
After these, the differentiated PC12 cells were pretreated
with various concentrations (60, 30, 15, 7.5, 3.75 μM) of
ligustrazine derivatives for 36 h. Then the cells were
induced by CoCl2 (final concentration, 200 mM) for
12 h. Control differentiated cells were injected with new
growth media at equal amounts. After MTT solution
(20 μL, 5 mg/mL) was added to each well, the plate was
incubated for a further 4 h at 37°C. The supernatant was
removed carefully without disturbing the attached cells
and formazan crystals were solubilized by adding 100 μL
DMSO into each well. After shaking for additional
15 min at 37°C, the plates were read for optical density
at 490 nm (Thermo Multiskan GO, USA). CoCl2 was
dissolved in RPMI 1640 medium. ligustrazine derivatives
were dissolved in DMSO [21,31-33].
Li et al. Chemistry Central Journal  (2015) 9:9 Page 9 of 9The proliferation rates of damaged PC12 cells were
calculated in the following formula [OD490 (Compd) −
OD490 (CoCl2)]/[OD490 (NGF) −OD490 (CoCl2)] × 100%;
the EC50 values were using the equation below: −pEC50 =
log Cmax − log 2 × (ΣP − 0.75 + 0.25Pmax + 0.25Pmin), Where
Cmax =maximum concentration, ΣP = sum of proliferation
rates, Pmax = maximum value of proliferation rate and
Pmin = minimum value of proliferation rate [18-21,34].
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